Search

Small cell lung cancer (SCLC) cells are missing a surface protein that triggers an immune response, allowing them to hide from one of the body’s key cancer defenses, a new study led by UT Southwestern researchers suggests.

Cancer cells salvage purine nucleotides to fuel tumor growth, including purines in foods we eat, an important discovery with implications for cancer therapies from research by Children’s Medical Center Research Institute at UT Southwestern published in Cell.

Scientists with UT Southwestern’s Peter O’Donnell Jr. Brain Institute have identified the molecular mechanism that can cause weight gain for those using a common antipsychotic medication.

UT Southwestern scientists may have identified a method of safely mimicking the weight-loss benefits of a plant compound that – despite its harmful side effects – hold critical answers to developing therapies for obesity.

Scientists have collected plenty of evidence linking exercise to brain health, with some research suggesting fitness may even improve memory.

A genetic marker discovered by UT Southwestern Medical Center researchers could help physicians predict which patients with hepatocellular carcinoma are most likely to develop resistance to the drug lenvatinib. The finding, published in the journal Gastroenterology, may lead to alternative

Tears or ruptures of the ulnar collateral ligament (UCL) are the most common elbow injury among baseball players from youth leagues to the major leagues, especially pitchers.

Patients with advanced cancer who also had cardiac defibrillators were more likely than those without these implants to receive aggressive end-of-life care, a team led by UT Southwestern Medical Center researchers found in a new study.

Reducing the level of body fat and waist size are linked to a lower risk of heart failure in patients with type 2 diabetes, a study led by UT Southwestern researchers indicates.

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) with KRAS mutations, a clinical trial led by UT Southwestern Harold C. Simmons Comprehensive Cancer Center researchers showed.